Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
Blood. 2021 Jan 7;137(1):103-114. doi: 10.1182/blood.2019002973.
Thrombin generation is pivotal to both physiological blood clot formation and pathological development of disseminated intravascular coagulation (DIC). In critical illness, extensive cell damage can release histones into the circulation, which can increase thrombin generation and cause DIC, but the molecular mechanism is not clear. Typically, thrombin is generated by the prothrombinase complex, comprising activated factor X (FXa), activated cofactor V (FVa), and phospholipids to cleave prothrombin in the presence of calcium. In this study, we found that in the presence of extracellular histones, an alternative prothrombinase could form without FVa and phospholipids. Histones directly bind to prothrombin fragment 1 (F1) and fragment 2 (F2) specifically to facilitate FXa cleavage of prothrombin to release active thrombin, unlike FVa, which requires phospholipid surfaces to anchor the classical prothrombinase complex. In vivo, histone infusion into mice induced DIC, which was significantly abrogated when prothrombin F1 + F2 were infused prior to histones, to act as decoy. In a cohort of intensive care unit patients with sepsis (n = 144), circulating histone levels were significantly elevated in patients with DIC. These data suggest that histone-induced alternative prothrombinase without phospholipid anchorage may disseminate intravascular coagulation and reveal a new molecular mechanism of thrombin generation and DIC development. In addition, histones significantly reduced the requirement for FXa in the coagulation cascade to enable clot formation in factor VIII (FVIII)- and FIX-deficient plasma, as well as in FVIII-deficient mice. In summary, this study highlights a novel mechanism in coagulation with therapeutic potential in both targeting systemic coagulation activation and correcting coagulation factor deficiency.
凝血酶生成对于生理血液凝固和弥散性血管内凝血 (DIC) 的病理发展都至关重要。在危重病中,广泛的细胞损伤会将组蛋白释放到循环中,这会增加凝血酶生成并导致 DIC,但分子机制尚不清楚。通常,凝血酶是由凝血酶原酶复合物生成的,该复合物由激活的因子 X (FXa)、激活的辅因子 V (FVa) 和磷脂组成,在钙离子存在下切割凝血酶原。在这项研究中,我们发现,在细胞外组蛋白存在的情况下,可以在没有 FVa 和磷脂的情况下形成替代的凝血酶原酶。组蛋白直接与凝血酶原片段 1 (F1) 和片段 2 (F2) 结合,以促进 FXa 切割凝血酶原释放活性凝血酶,这与需要磷脂表面来锚定经典凝血酶原酶复合物的 FVa 不同。在体内,将组蛋白注入小鼠会诱导 DIC,而在注入组蛋白之前先注入凝血酶原 F1+F2 作为诱饵,则可显著减轻 DIC。在一组伴有败血症的重症监护病房患者中(n=144),DIC 患者的循环组蛋白水平显著升高。这些数据表明,无磷脂锚定的组蛋白诱导的替代凝血酶原酶可能会弥散性血管内凝血,并揭示了凝血酶生成和 DIC 发展的新分子机制。此外,组蛋白还显著降低了凝血级联反应中 FXa 的需求,从而使 VIII 因子 (FVIII) 和 FIX 缺乏的血浆以及 FVIII 缺乏的小鼠能够形成血栓。总之,这项研究强调了凝血中的一种新机制,具有靶向全身性凝血激活和纠正凝血因子缺乏的治疗潜力。